Skip to main content
. 2023 Feb 28;18(2):e0281004. doi: 10.1371/journal.pone.0281004

Fig 3. pXRD analysis of 5-FU (A), Precirol® ATO5 (B), Poloxamer 188 (C), Physical mixture (D), and optimized formulation (E).

Fig 3